GlassScriptPhysician profile
Lindsay N Jayson
NPI 1669449567
$12,815.53
in general payments reported to CMS, 2019-2025
26 companies · $2,347 in 2025
The $2,347 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,452 · 2022: $2,831 · 2023: $3,126 · 2024: $3,059 · 2025: $2,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,250 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,250.07 |
| Education | $282.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,024.38 | 2021-2025 | |
| Janssen Biotech, INC. | $1,396.41 | 2021-2025 | Tremfya, Stelara, Simponi |
| Medimetriks Pharmaceuticals, INC. | $1,239.04 | 2022-2025 | Clindacin Etz, Neuac, Neo-Synalar |
| Genzyme Corporation | $823.23 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $733.11 | 2021-2025 | Cabtreo, Jublia |
| Journey Medical Corporation | $695.95 | 2021-2025 | |
| Dermavant Sciences, INC. | $560.07 | 2022-2024 | Vtama |
| Ucb, INC. | $501.77 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $479.56 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $413.21 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $369.31 | 2021-2025 | |
| Incyte Corporation | $363.07 | 2021-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $355.33 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $329.18 | 2021-2024 | Winlevi, Blu-U, Odomzo |
| Novartis Pharmaceuticals Corporation | $292.38 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $282.50 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $222.48 | 2022-2025 | Dupixent |
| Pfizer INC. | $147.46 | 2021-2025 | |
| Leo Pharma INC. | $147.21 | 2021-2025 | Anzupgo |
| Vyne Pharmaceuticals INC. | $140.43 | 2021 | |
| Arcutis Biotherapeutics, INC. | $120.52 | 2023-2025 | Zoryve |
| Organon LLC | $104.49 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $35.54 | 2023 | Ycanth |
| Allergan, INC. | $13.40 | 2022 | |
| Almirall LLC | $12.85 | 2023 | Seysara |
| Biofrontera INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Jayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.